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Age-related macular degeneration (AMD) is a late-onset, neurodegenerative retinal disease that shares several clinical and patho-
logical features with Alzheimer’s disease (AD) including extracellular deposits containing amyloid-b (Ab) peptides. Immunotherapy
targeting the Ab protein has been investigated as a potential treatment for AD. Here, we present the rationale for extending this
approach to treat AMD. We tested an anti-Ab antibody administered systemically in a mouse model of AMD. Histological and func-
tional measurements in treated animals compared to controls showed that following immunotherapy, the amounts of Ab in the retina
and brain were decreased and the ERG deﬁcits in the retina were attenuated. These data support the hypothesis that Ab is a ther-
apeutic target for AMD.
 2007 Elsevier Ltd. All rights reserved.
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Age-related macular degeneration (AMD) is a late-onset
neurodegenerative retinal disease that manifests as progres-
sive loss of central vision due to dysfunction and death of
photoreceptor and adjacent retinal pigment epithelial
(RPE) cells in the macula. It is the leading cause of irrevers-
ible vision loss in people over the age of 65 (Javitt, Zhou,
Maguire, Fine, & Willke, 2003). AMD is a multifactorial0042-6989/$ - see front matter  2007 Elsevier Ltd. All rights reserved.
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E-mail address: bowes007@duke.edu (C. Bowes Rickman).disease in which the relative contributions of genetic and
environmental factors remain unknown. The strongest
known risk factor for AMD is advanced age, however,
other identiﬁed risk factors include gender, ethnicity,
smoking, hypertension, hypercholesterolemia, and diet
(van Leeuwen, Klaver, Vingerling, Hofman, & de Jong,
2003). It is now established that AMD is also inﬂuenced
by genetic factors, as evidenced by identiﬁcation of
AMD-susceptibility genes (Evans & Bird, 1996; Heiba,
Elston, Klein, & Klein, 1994; Klein, Mauldin, & Stoumbos,
1994; Klein et al., 1998; Piguet et al., 1993; Silvestri, John-
ston, & Hughes, 1994). One gene implicated is APOE, a
polymorphic gene in humans encoding one of three com-
mon alleles (e2, e3 and e4) with the e4 allele associated with
AMD (Baird, Guida, Chu, Vu, & Guymer, 2004). Apolipo-
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ates the distribution of lipids and cholesterol among cells.
A Y402H polymorphism in another gene, CFH, coding
for complement factor H and factor H-like protein 1, was
recently shown to be the major genetic factor contributing
to AMD (Edwards et al., 2005; Hageman et al., 2005;
Haines et al., 2005; Klein et al., 2005).
2. Mouse model of AMD
We developed a murine model of AMD that combines
three known risk factors for AMD: advanced age, apoE
isoform expression and exposure to a high-fat, choles-
terol-enriched (HF-C) diet (Malek et al., 2005). Speciﬁ-
cally, mice carrying a targeted knock-in of the human
APOE e4 (APOE4) gene, aged over 1 year and fed a HF-
C diet for 8 weeks develop pathological features similar
to the morphologic hallmarks observed in both dry and
wet human AMD. Importantly, these changes require the
presence of all three risk factors. These changes were not
detected in any of the control, human APOE3 expressing
mice regardless of diet consumed, nor were there any
pathologies detected in young APOE4 animals. This ani-
mal model of AMD with spontaneously-occurring CNV
is the ﬁrst to incorporate physiologically-relevant risk fac-
tors of human disease and therefore can be used to ratio-
nally identify and test therapeutic targets for
intervention. To date, the results of our studies using this
model suggest that lipid transport dysregulation and amy-
loid deposition contribute to the pathogenesis of the
observed retinal changes (Malek et al., 2005).
3. Alzheimer’s disease, amyloid and Ab
Like AMD, AD is a multifactorial disease aﬀected by
age, environmental factors and genetics. In AD the major
genetic risk factor is APOE. The common APOE gene
polymorphisms are linked to 90% of cases <65 years of
age and 60% of AD cases >65 years. Whereas the function
of apoE in the central nervous system remains unclear,
apoE functions in the periphery by maintaining cholesterol
and triglyceride homeostases (Mahley, 1988). The patho-
logical hallmarks of AD include the presence of senile pla-
ques, neuroﬁbrillary tangles, neuronal cell loss, reactive
gliosis and, in some cases, cerebrovascular amyloid depos-
its (reviewed by Blennow, de Leon, & Zetterberg, 2006).
Senile plaques are generated by deposition and accumula-
tion of the amyloid-b (Ab) peptides. Cholesterol has been
linked to amyloidogenesis, and there is increasing evidence
of the importance of cholesterol as a risk factor for AD
through both intracellular and extracellular mechanisms
(Canevari & Clark, 2007).
Ab peptides are derived from amyloid precursor protein
(APP) through sequential, proteolytic cleavage at the N-
terminus by b-secretase and at the C-terminus by c-secre-
tase. The c-secretase is unique among proteases in that it
cleaves APP in the transmembrane region, resulting in apeptide of 40 or 42 amino acids in length (Ab1–40 or
1–42). After Ab1–40 or 1–42 peptides are generated, its
N-terminus can be further modiﬁed or cleaved, yielding
N-terminal truncated peptides Abx-40 or Abx-42 (Arai,
Akiyama, Ikeda, Kondo, & Mori, 1999). Mutations of
APP and presenilins (PS1 and PS2, integral components
of the c-secretase protease complex) have been identiﬁed
in familial forms of AD. APP-overexpressing and APP/
PS1 double transgenic mice exhibit brain deposits of
amyloid (plaques) and accompanying memory impairment,
underscoring the notion that accelerated Ab peptide pro-
duction is suﬃcient to lead to AD.
4. Ab immunotherapies
Immunotherapies targeting the Ab peptide, using vac-
cines or antibodies, have been applied to several diﬀerent
strains of APP-based mouse models of AD to reduce amy-
loid plaques and improve cognitive performance (Hardy &
Selkoe, 2002). Although promising, phase 2 clinical trials
of the ﬁrst generation Ab vaccine AN-1792 (Elan/Wyeth)
were halted after a signiﬁcant number of patients (6%)
developed autoimmune meningoencephalitis characterized
by perivascular inﬁltration, due primarily to brain inﬁltra-
tion of autoreactive T lymphocytes in response to active
immunization (Ferrer, Boada Rovira, Sanchez Guerra,
Rey, & Costa-Jussa, 2004; Nicoll et al., 2003; Orgogozo
et al., 2003). Importantly, unlike typical AD patients, the
AN-1792 treated AD patients undergoing autopsy were
found to have extremely low amyloid burdens in their cere-
bral cortex, suggesting the tantalizing possibility that the
vaccine was, in fact, eﬀective in removing the amyloid pla-
ques (Masliah et al., 2005; Nicoll et al., 2003).
To reduce the risk of uncontrolled CNS inﬂammation
associated with active vaccines, passive immunization using
a monoclonal antibody targeting the N-terminus (Bap-
ineuzumab, Elan/Wyeth) or the middle portion
(LY2062430, Eli Lilly) of the Ab peptide are now under
investigation in phase 2 clinical studies (Melnikova,
2007). However, as mentioned above, the N-terminal por-
tion of Ab peptides are often truncated, rendering the
monoclonal antibodies targeting the N-terminus ineﬀective
for these truncated Ab peptides in the AD brain. On the
other hand, antibodies recognizing the middle portion of
the Ab peptides can also bind the full length APP protein
normally found on the cell surface in the CNS, creating a
potential safety risk for neurons and other healthy APP
expressing cells in patients.
Therefore, we turned our attention to the novel thera-
peutic approach of targeting Ab peptides at the C-termi-
nus. These C-terminal epitopes are normally buried in the
lipid bilayer and are exposed, predominantly, in the patho-
logical state. Two diﬀerent C-terminal x-40 speciﬁc mono-
clonal antibodies, 2286 and 2H6, were identiﬁed and tested
in Tg2576 APP-overexpressing mouse model (Wilcock
et al., 2004). Both antibodies, given either intracranially
or peripherally, were eﬀective in reducing brain levels of
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peripheral administration of these C-terminal x-40 speciﬁc
antibodies was also accompanied by a 10- to 100-fold
increase in circulating Ab peptide levels, supporting the
notion that Ab antibodies in the periphery create a sink,
pulling soluble brain Ab into the blood for clearance. Since
both 2286 and 2H6 antibodies have native mouse immuno-
globulin constant regions that can mediate immune eﬀector
functions, such as binding to Fcc receptors, complement
ﬁxation and antibody-dependent cell-mediated cytotoxicity
(ADCC), we sought to further reduce the potential safety
risk of C-terminal speciﬁc Ab antibodies. In previous stud-
ies, deglycosylated 2H6 (i.e. 2H6-D) did not bind any Fcc-I
receptors, complement or mediate any detectable ADCC.
The administration of 2H6-D in Tg2576 mice, while still
eﬀective in ameliorating the AD pathology and behavioral
deﬁcits, was associated with signiﬁcantly lower levels of
microhemorrhages and inﬂammation in the brain than
the parent antibody, 2H6 (Carty et al., 2006; Wilcock
et al., 2006).
5. Rationale for Ab immunotherapy in AMD
As mentioned above, AD and AMD share several
striking pathological features in common. First and fore-
most, the risk of AD and AMD both increase dramati-
cally with advanced age. Furthermore, they are both
associated with pathological, extracellular deposits con-
sisting of Ab peptides, apoE protein, complement and
other components.
In human AMD, Ab deposition was associated with
drusen from AMD eyes, but not with drusen in normal
eyes (Dentchev, Milam, Lee, Trojanowski, & Dunaief,
2003), where it accumulates and co-localizes with activated
complement components within drusen (Anderson et al.,
2004; Johnson et al., 2002). Likewise, we detected Ab pep-
tide in aged APOE4 mice exposed to a HF-C diet (APOE4-
HFC) but not in control animals (Malek et al., 2005). In
addition, human CNV membranes and neovascular (NV)
tissue from APOE4-HFC mice display perivascular Ab
immunoreactivity, whereas Ab immunoreactivity was also
detected in subRPE deposits in our AMD model (Malek
et al., 2005). A pathogenic role for amyloid in AMD was
proposed by Yoshida et al. in studies showing that Ab
increases VEGF mRNA and protein levels in primary cul-
tures of human RPE cells, (Yoshida et al., 2005), and evi-
dence of amyloid toxicity was shown by Luibl et al. who
detected nonﬁbrillar oligomeric Ab in drusen from AMD
eyes (Luibl et al., 2006).
Based on (1) the detection of amyloid in both our animal
model and in AMD patients, (2) the ﬁndings that APOE
genotype regulates Ab cytotoxicity and (3) the considerable
overlap between the pathologies of AMD and AD, we
tested the hypothesis that Ab is a toxic, pathogenic compo-
nent of basal deposits by using an anti-Ab antibody to
deplete Ab in a mouse model of AMD to determine if this
could ameliorate the disease.6. Pilot study of anti-Ab in AMD mouse
6.1. Methods
6.1.1. Animals
Mice were maintained and bred in accordance with the
Institutional Animal Care and Use Committee at Duke
University and the Association for Research in Vision
and Ophthalmology statement for the use of animals in
ophthalmic and vision research. APOE4 targeted replace-
ment (TR) mice expressing the human apoE4 isoform
under control of the endogenous mouse apoE regulatory
sequences, were generated as previously described (Sullivan
et al., 1997).
6.1.2. Experimental protocol, diet and antibody
administration paradigm
A small cohort of aged male (n = 19; 72–120 weeks)
C57Bl/6 APOE4 TR mice housed conventionally, under
ambient conditions were switched from normal mouse
chow (ND, Isopurina #5001; Prolab, Dewitt, NY) to a
high fat diet rich in cholesterol (HF-C, #T.D. 88051; Har-
lan Teklad, Indianapolis, IN) for 8 weeks immediately
prior to analysis as previously described (Malek et al.,
2005). Age-matched normal control APOE4 TR littermates
(‘‘APOE4-ND’’, n = 3) were fed ND and water ad libitum.
The HF-C fed APOE4 mice (APOE4-HFC) were assigned
to one of three groups based on antibody treatment as
follows:
(1) Uninjected controls (n = 3), ‘‘APOE4-HFC-uninj’’,
received no injections.
(2) Vehicle injected controls (n = 8), ‘‘APOE4-HFC-
PBS’’, received 1· per week intraperitoneal (IP) injec-
tions of vehicle (phosphate buﬀered saline, PBS) for a
period of 8 weeks coinciding with HF-C diet.
(3) Anti-Ab injected (n = 8), ‘‘APOE4-HFC-Anti-Ab’’,
received 1· per week IP injections of 3 mg/kg body
weight/injection of 2H6-D (deglycosylated anti-
Ab33–40; IgG2b isotype; Rinat Neurosciences, South
San Francisco, CA) which recognizes both mouse
and human Ab (Wilcock et al., 2004, 2006).
Antibodies, antibody doses and injection paradigm used
were based on parameters established by previously in AD
mouse models (Wilcock et al., 2006). At the end of the diet/
injections exposure, mice were euthanized with an overdose
of avertin and ﬂushed with a 20 ml bolus of saline.
6.1.3. Electroretinogram (ERG) recordings
The ERG recordings were obtained from animals, dark
adapted for at least 12 h prior to recording. Each animal
was anesthetized with a ketamine/xylazine cocktail, pupils
were dilated and after the animal stabilized on a 37 C
warming pad, ERG tracings were recorded using a silver
ﬁber test electrode placed in contact with the eye along with
a drop of 2.5% hydroxypropyl methylcellulose. Each
Fig. 1. b-wave in aged APOE4 mice fed a normal or HF-C diet and
in aged APOE4-HFC’s injected with anti-Ab antibody (HFC-aAb) or
with saline vehicle control (HFC-con). V-log I intensity response
curves of the b-waves. Baseline ERGs (n = 12–14) obtained from
APOE4-ND controls (black) and APOE4-HFC controls (red). E4-
HFC-con vehicle injected (green), E4-HFC-aAb (blue). Data are
plotted with SE bars. The b-wave in the antibody-treated animals is
preserved compared to the saline-treated group (p < 0.2, equal variance
two-tailed t-test).
Fig. 2. Amyloid detected in APOE4 mouse retina using 4G8 anti-Ab antibody
injected control, (C) APOE4-HFC injected with anti-Ab antibody, 2H6-D. N
HFC vehicle injected control retina (arrowheads in B), but not in antibody tr
yellow puncta (A, B and C). (D) Summary and statistical results of Ab linear
animals. Bars and error bars show averaged density and standard deviation
signiﬁcantly reduced compared to saline-treated group (p = 0.048, one-tailed t
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1000 cd-s/m2 attenuate in 1 log steps, starting from
0.0005). The a-wave amplitude was measured from baseline
to the a-wave trough, and the b-wave amplitude was mea-
sured from the a-wave trough to the b-wave peak.
6.1.4. Histology and immunohistochemistry
Eyes were immersion ﬁxed in 4% paraformaldehyde for
2 h and transferred to 2% paraformaldehyde and stored at
4 C until processing for light microscopy. The anterior
segment was removed and posterior segment was cryo-pro-
tected with serial sucrose (10%, 20% and 30%) solution.
Frozen sections were cut on a cryostat at 10 lm. Sections
were treated with 3% H2O2 for 30 min, preincubated with
10% BSA, and incubated overnight with biotinylated
monoclonal mouse anti-Ab antibody (1:100; clone 4G8,
Signet). The signal was then ampliﬁed using a TSA biotin
kit (Perkin-Elmer), following the manufacturer’s instruc-
tions. Sections were then incubated with streptavidin-con-
jugated Alexa Fluore 594, to visualize the signal. For
quantiﬁcation, 3–4 images were randomly taken for each
of ﬁve antibody-treated and ﬁve saline-treated animals.
Ab-positive puncta in basal deposits and BM were(A–C) and quantiﬁcation (D). (A) APOE4-ND, (B) APOE4-HFC vehicle
ote positive Ab staining (red) along Bruch’s membrane (BM) in APOE4-
eated APOE4-HFC mouse retina (C). Lipofuscin autoﬂuorescence: bright
density along BM. Black dots represent average Ab density for individual
. The linear density of Ab-positive puncta of antibody-treated group is
-test).
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are presented as linear density along BM.
The brain was immersion ﬁxed in 10% buﬀered forma-
lin (4% formaldehyde, pH 7.4) for 18 h at 4 C, prior to
being transferred to 1· PBS, pH 7.4, 4 C. The brain was
then sagitally sectioned on an Oxford vibratome at
30 lm then reacted as free-ﬂoating sections. Ab immuno-
histochemistry (IHC) was performed with the biotin-avi-
din-peroxidase method, using diaminobenzidine (DAB)
as a chromogen (Vector Laboratories, CA). All tissue
sections including controls are run simultaneously to
avoid inter-run variability. No antibody was used for
visualizing background reactivity for negative control
for each animal. IHC tissue is pretreated in 10% metha-Fig. 3. Amyloid in mouse brain (cortex) using 4G8 anti-Ab antibody. Amyloi
2H6-D. (A and C) Representative sections through the cortex of apoE4 treate
amyloid even in the vascular regions of the tissue. (B and D) Control aged apoE
(E) Negative control with no antibody was used to measure background stain
human amyloid in the brain) was used for amyloid positive control (gift fromnol and 2% peroxide in PBS and then 88% formic acid
for 1 min. After blocking in serum, the tissue is incu-
bated with a biotinlyated mouse anti-human Ab mono-
clonal (1:2000) (4G8, Senetek, Napa, CA) at room
temperature, 2 h. The tissue is then incubated with an
avidin-biotin conjugate ABC reagent, as manufacture
instructions (Vector Laboratories, CA). DAB (1.39 mM)
in 1· PBS, 0.01% peroxide is used as the chromogen
for visualization of staining. No secondary staining was
used. Stained slides were examined under light micros-
copy (Nikon optiphot-2). In order to eliminate any bias
in analyzing the tissue, several pictures from each section
were digitally captured by a cooled CCD camera Pen-
guin 660cl (Pixera).d deposits decreased in aged APOE4-HFC treated with anti-Ab-antibody,
d mice stained with an anti-amyloid-b antibody (4G8) showing almost no
4 mice on HF-C diet showing an occasional parenchymal amyloid deposit.
ing. (F) Human transgentic PdAPP mouse tissue (a mouse that deposits
Kelly Bales, Eli Lilly).
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6.2.1. ERG recordings
We have previously shown that aged APOE4 animals
following exposure to the HF-C diet for 8 weeks
(APOE4-HFCs) develop AMD-associated ocular patholo-
gies (Malek et al., 2005), and that in these animals there
was statistically signiﬁcant reduction in the a- and b-wave
amplitudes compared to age-matched, histologically nor-
mal control APOE4 mice maintained on the normal rodent
chow diet, APOE4-ND (Malek, Jamison, Mace, Sullivan,
& Bowes Rickman, 2007). In the current pilot cohort of
aged APOE4-HFC mice that were either uninjected or
received 8 weekly IP injections of the saline-control a sim-
ilar decrease in the b-wave amplitudes was observed com-
pared to the normal APOE4-ND (Fig. 1). In contrast,
there was a preservation of the b-wave amplitude in the
APOE4-HFC mice that received 8 weekly IP injections of
the anti-Ab antibody (blue trace, Fig. 1). A similar trend
was observed in the a-wave amplitudes though it was not
as robust (data not shown).
6.2.2. Amyloid immunohistochemistry
Consistent with the improvement of ERG, total Ab
immunostaining in the retina of the E4-HFC mice was
reduced after 8 weeks immunotherapy with antibody
2H6-D as compared to the control vehicle group, as illus-
trated in Fig. 2. On average, the control saline-treated
group had 116 puncta per 1 mm of BM, whereas anti-Ab
antibody-treated group had 41 (Fig. 2; p = 0.048, one-
tailed t-test). Similarly, the diﬀuse amyloid plaques
revealed by the total Ab immunostaining in the cerebral
cortex of the E4-HFC mice were also greatly reduced after
8 weeks immunotherapy with antibody 2H6-D relative to
the control vehicle group (Fig. 3). Vascular amyloid in
the brain was more prevalent in untreated E4-HFC animals
(not shown).
These preliminary ﬁndings demonstrate (1) preservation
of retinal function as demonstrated by ERGs of mice
injected with the anti-Ab antibody, 2H6-D and 2) reduc-
tion of amyloid deposition when treated with anti-Ab anti-
body in mouse retina and cortex as compared to the
untreated AMD mouse group.
7. Summary and future directions
Despite the shared similarities between AD and AMD,
AMD has thus far not been classiﬁed as an amyloid dis-
ease. Among the principal diﬀerences is the fact that classi-
cal amyloid diseases typically exhibit large amounts of
amyloid ﬁbrils (Soto, 2003). For example, in the case of
AD, the characteristic plaques consist primarily of ﬁbrillar
Alzheimer Ab peptide. Amyloid ﬁbrils display characteris-
tic tinctorial properties, such as thioﬂavin T and congo red
staining (Krebs, Bromley, & Donald, 2005; LeVine, 1999;
Puchtler & Sweat, 1965). Though drusen do stain with thi-
oﬂavin T and congo red, the characteristic birefringenceoften seen in congo red-stained amyloid ﬁbrils is not pres-
ent (Anderson et al., 2004; Mullins, Russell, Anderson, &
Hageman, 2000).
Even though AMD is not widely considered as a proto-
typical amyloid disease, previous studies from several lab-
oratories, including ours, have localized Ab peptide-
derived amyloid within subRPE deposits and CNV in
human AMD eyes and our murine model implicate Ab
amyloid in AMD pathogenesis. This is further supported
by our pilot immunotherapy study targeting Ab described
above.
These ﬁndings, though preliminary, contribute to under-
standing underlying mechanisms of pathology speciﬁcally
related to the role of amyloid in sub-RPE deposit forma-
tion and retinal changes in AMD. These experiments sup-
port the feasibility of immunotherapeutic strategies
targeting amyloid as treatments for AMD. Finally, our
pilot data also suggest the exciting prospect that, in the
aging population, two of the most common neurodegener-
ative diseases, AD and AMD, could simultaneously be
treated or prevented with a single therapeutic agent, such
as the anti-Ab antibody.Acknowledgments
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